119 related articles for article (PubMed ID: 23145797)
1. Ether à go-go 1 silencing in combination with TRAIL overexpression has synergistic antitumor effects on osteosarcoma.
Wu J; Zeng T; Wu X; Gao Q; Zhai W; Ding Z
Cancer Biother Radiopharm; 2013 Feb; 28(1):65-70. PubMed ID: 23145797
[TBL] [Abstract][Full Text] [Related]
2. Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling.
Wu J; Wu X; Zhong D; Zhai W; Ding Z; Zhou Y
Int J Mol Sci; 2012 Oct; 13(10):12573-83. PubMed ID: 23202914
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma].
Chen ZD; Liu QJ; Zeng WR; Wu XY; Lin B; Wu J
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):818-825. PubMed ID: 27998439
[No Abstract] [Full Text] [Related]
4. Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression.
Wu J; Zhong D; Fu X; Liu Q; Kang L; Ding Z
Int J Mol Sci; 2014 Apr; 15(4):5570-81. PubMed ID: 24694542
[TBL] [Abstract][Full Text] [Related]
5. Silencing of Eag1 Gene Inhibits Osteosarcoma Proliferation and Migration by Targeting STAT3-VEGF Pathway.
Wu X; Chen Z; Zeng W; Zhong Y; Liu Q; Wu J
Biomed Res Int; 2015; 2015():617316. PubMed ID: 26783521
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC.
Pan Q; Liu B; Liu J; Cai R; Liu X; Qian C
Acta Oncol; 2008; 47(1):135-44. PubMed ID: 17934893
[TBL] [Abstract][Full Text] [Related]
7. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
8. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.
Fan L; Zhu C; Qiu R; Zan P; Zheng Z; Xu T; Li G
Cell Physiol Biochem; 2017; 41(5):1935-1946. PubMed ID: 28391262
[TBL] [Abstract][Full Text] [Related]
10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
13. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
Kim DR; Park MY; Lee CS; Shim SH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Cancer Gene Ther; 2011 Jul; 18(7):467-77. PubMed ID: 21455254
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression.
Wu X; Zhong D; Gao Q; Zhai W; Ding Z; Wu J
Int J Med Sci; 2013; 10(6):676-82. PubMed ID: 23569431
[TBL] [Abstract][Full Text] [Related]
15. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer.
Tu SP; Liston P; Cui JT; Lin MC; Jiang XH; Yang Y; Gu Q; Jiang SH; Lum CT; Kung HF; Korneluk RG; Wong BC
Int J Cancer; 2009 Aug; 125(3):688-97. PubMed ID: 19358264
[TBL] [Abstract][Full Text] [Related]
16. Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma.
Wang Y; Li L; Shao N; Hu Z; Chen H; Xu L; Wang C; Cheng Y; Xiao J
Acta Biomater; 2015 Apr; 17():115-24. PubMed ID: 25595474
[TBL] [Abstract][Full Text] [Related]
17. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
18. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
19. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells.
Liu G; Yu MY; Huang X; Zhu D; Cheng S; Ma R; Gu G
Mol Med Rep; 2014 Oct; 10(4):2198-202. PubMed ID: 25050836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
